In OTC Tests, Naloxone Absorption Slowed When Administered After Subjects Had Used Masks

Harm Reduction Therapeutic Among Nonprofits Backing Affordable Drugs Bill

Testing results for subjects who wore face masks before and after intranasal administration suggest early absorption of naloxone was adversely affected. Expanding Access to Affordable Prescription Drugs and Medical Devices Act would provide support for nonprofits such as Harm Reduction Therapeutics, which continues research for an NDA for an OTC naloxone nasal spray.

Results from Harm Reduction Therapeutics Inc.'s bioavailability testing for an OTC intranasal naloxone showed "an unexpected side effect of the COVID-19 pandemic,” says the firm's CEO.

While Pittsburgh-based Harm Reduction Therapeutics continues OTC naloxone research and development, it looks to legislation recently introduced in the Senate...